Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

APREMILAST

APREMILAST

Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview APREMILAST is listed in Drugs@FDA under application 211897 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient APREMILAST Form and strength TABLET;ORAL - 30MG Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2022-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview APREMILAST is listed in Drugs@FDA under application 211897 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient APREMILAST Form and strength TABLET;ORAL - 30MG Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2022-08-18 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.